TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2004
Have a very good pipeline. Faces significant generic exposure for the next few years because of patent exposure. On his focus list and will probably stay there for some time.
Photo of Matt BaraschMatt Barasch
No
Unlock Rating
$37.28

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 17, 2004
Feels it is going to move substantially higher in the next 12/18 months.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$37.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Feb 10, 2004
Had a good run. Benefit you to wait. Buy when it is down a few dollars from current price.
Photo of Brad WillockBrad WillockUnlock Rating
$38.00

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 15, 2004
A great pharmaceutical company. Has a huge stable of drugs coming through.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.82

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 07, 2004
(A past top pick Dec 6/03. Up 6.7%.) Still likes it. A tremendous pipeline. Not facing a lot of patent issues. Very reasonable valuation. Will be a solid 15/20% grower.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$36.79

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 29, 2003
Pharmaceutical companies have been laggards. Should have revenue growth of about 40% and earnings at about 20% in 2004. 2 1/2% dividend.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$35.00

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 12, 2003
One of the best pharmaceutical companies. The large pharmaceutical companies are increasingly facing more and more headwinds. If it reaches the upper $30's, consider selling.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$34.40

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 01, 2003
Trading at 15X 2004 earnings. Will have a growth rate of 15/20%. Well diversified number of drugs. Nothing coming off patent until 2007. The whole area has been hit hired on the concerns of US pricing of drugs, but feels the bill will be positive.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$34.17

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2003
(A top pick July 10/03. No change.) There is something wrong with the drug stocks. They are all trading poorly and he thinks they want to go lower.
Photo of Ross HealyRoss HealyUnlock Rating
$33.57

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 19, 2003
Will have 100 different drugs in the next 3 or 4 years. Have enormous cash flow. Paying down their debt. Debt/equity ratio is quite strong. Weak US$ will be of benefit as they are international. 2% dividend.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$34.18

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2003
Pharmaceutical sector has been very frustrating. OK buy for a long-term investment. Could still be some downside. Expecting to file 22 to 25 new drugs between now and 2006. Generates tremendous cash flow. Earnings visibility is good.
Photo of Stephane RochonStephane RochonUnlock Rating
$30.97

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 15, 2003
(A top pick Sep 19/03. Down 1.8%.) Still likes the area and this is the premier company.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$30.60

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 03, 2003
Drug industry has been experiencing difficulties over the past 12 months. Thinks the industry has growth going forward.
Photo of Ray SteeleRay SteeleUnlock Rating
$30.78

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 29, 2003
Viagra is about to have its first major competitor, which could be a significant threat. Pharmaceutical industry suffers from trademark litigations.
Photo of David BaskinDavid BaskinUnlock Rating
$30.89

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 26, 2003
One of the best pharmaceutical companies but have concerns about pharmaceutical companies because of a lot of pressure on prices. The pipeline, two to three years out looks pretty thin.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. Sc
Owned
Unlock Rating
$30.56

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 751 to 765 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like